SALT LAKE CITY, September 8, 2021 – Depression medication trial and error is far too common – and may result in additional mental health challenges.
GeneSight® Mental Health Monitor finds large gap between what Americans think and what they actually know about recognizing depression. SALT LAKE CITY, July 28, 2021 – Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced results from a recent nationwide poll, the GeneSight® Mental Health Monitor.
SALT LAKE CITY, April 28, 2021 – In a new nationwide poll, the GeneSight® Mental Health Monitor found that 83% of people with depression agree that life would be easier if others could understand their depression. Yet, most people who have not experienced depression may not be able to understand the challenges, including its treatment.
